19.00
+0.04(+0.21%)
Currency In USD
Address
10 Hudson Yards
New York City, NY 10001
United States of America
Phone
646 747 1000
Sector
Healthcare
Industry
Biotechnology
Employees
341
First IPO Date
October 11, 2012
| Name | Title | Pay | Year Born |
| Mr. Jerome B. Durso | President, Chief Executive Officer & Director | 1.37M | 1968 |
| Mr. David Ford | Chief Human Resources Officer | 434,904 | 1970 |
| Mr. Rocco Venezia | Chief Accounting Officer & Treasurer | 660,625 | 1976 |
| Mr. Jared M. Freedberg J.D. | General Counsel | 812,554 | 1968 |
| Ms. Linda M. Richardson | Executive Vice President & Chief Commercial Officer | 837,730 | 1964 |
| Mr. Andrew Saik | Chief Financial Officer | 888,600 | 1969 |
| Dr. M. Michelle Berrey M.D., M.P.H. | President of Research & Development and Chief Medical Officer | 1.12M | 1967 |
| Dr. M. Michelle Berrey M.D., M.P.H., MPH. | Pres of R&D and Chief Medical Officer | 1.12M | 1967 |
| Dr. Mark Pruzanski M.D. | Founder, Advisor & Director | 1.3M | 1968 |
| Paul Nitschmann | Senior Vice President of Regulatory Affairs | 0 | N/A |
| Mr. Nareg Sagherian | Executive Director of Global Investor Relations | 0 | N/A |
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. It markets its products through an internal commercial organization and third-party distributors. The company was incorporated in 2002 and is headquartered in New York, New York.